Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Why It Matters

The data validate an oral, disease‑modifying therapy for sickle‑cell disease, expanding options beyond hydroxyurea and transfusions, and bolster Agios's supplemental NDA for accelerated FDA approval.

Key Takeaways

• Mitapivat raised hemoglobin ≥1 g/dL in 40.6% vs 2.9% placebo.
• Transfusion need fell 41% relative; units per patient down 56%.
• Hemoglobin responders cut sickle‑cell pain crises by 26% and ER visits 53%.
• Patient‑reported fatigue improved beyond clinical threshold for responders.
• Adverse events similar to placebo; no treatment‑related deaths observed.

Pulse Analysis

Sickle‑cell disease remains a high‑unmet‑need condition, with patients relying on hydroxyurea, chronic transfusions and occasional gene‑editing therapies. These approaches address symptoms but do not fully correct the underlying hemolysis that drives vaso‑occlusive crises. Mitapivat, an oral pyruvate‑kinase activator, targets red‑cell metabolism to increase ATP and lower 2,3‑DPG, theoretically reducing sickling propensity and offering a novel, patient‑friendly treatment modality.

The RISE UP Phase 3 trial delivered compelling efficacy signals. Over half of the mitapivat cohort achieved the primary hemoglobin response, translating into a 41% relative drop in patients needing transfusions and a 56% reduction in units per patient—outcomes that directly lessen transfusion‑related complications and healthcare costs. Sub‑analyses revealed that responders enjoyed 26% fewer pain crises, 34% fewer hospitalizations and a striking 53% reduction in emergency‑room visits, while patient‑reported outcomes such as fatigue, pain intensity, physical function and sleep all surpassed clinically meaningful thresholds. Importantly, the safety profile mirrored placebo, with no treatment‑related deaths, reinforcing confidence in long‑term tolerability.

Regulatory and commercial implications are significant. Agios has already filed a supplemental NDA seeking accelerated approval, and the robust data set positions mitapivat as a differentiated oral therapy in a market dominated by injectable and gene‑based options. If approved, the drug could capture a sizable share of the global sickle‑cell market, improve quality of life for thousands of patients, and set a precedent for metabolic activation strategies in other hemolytic disorders. Competitors will need to address similar mechanistic pathways to stay relevant, while payers may favor an oral agent that reduces transfusion and hospitalization expenditures.